A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer
Status:
Withdrawn
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Phase 1 - open label, multi-center, non-randomized, safety, pharmacokinetic and
pharmacodynamics dose escalation study of PF-06459988 as a single agent in patients with
advance EGFRm NSCLC (del 19, L858R, +/- T790M). The resulting PF-06459988 dose selected from
the phase 1 portion will undergo a series of sub-studies to fully characterize the impact of
food, antacid and CYP3A4 inhibitors/inducers. The PK studies are in addition to the MTD
expansion and will be completed prior to the initiation of Phase 2. Phase 2 is an open label,
multi-center single-arm study of PF-06459988 for the assessment of antitumor activity in
patients with advanced EGFRm (del 19 or L858R) NSCLC with T790M.